![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sinovac Begins Phase 3 COVID-19 Vaccine Trial in Indonesia
Sinovac Begins Phase 3 COVID-19 Vaccine Trial in Indonesia
![COVID-19 Clinical Trial](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-CLINICAL-TRIAL.gif?t=1585696642&width=430)
Chinese drugmaker Sinovac has begun a phase 3 trial of its COVID-19 vaccine CoronaVac in Indonesia in partnership with state-owned Indonesian drugmaker Bio Farma.
CoronaVac uses an inactivated form of the coronavirus to prompt an immune response. In a phase 2 trial, it induced neutralizing antibodies in 90 percent of participants.
The only local vaccine manufacturer in Indonesia, Bio Farma expects to begin commercial production in six months. CoronaVac is also in phase 3 testing in Brazil.
Upcoming Events
-
21Oct